. 2014 Aug 19;9(8):e104902. doi: 10.1371/journal.pone.0104902

Table 4. KRAS mutation status in primary tumor and corresponding CTC-enriched samples in mCRC patients.

	Primary tumor	CTC-enriched fraction
Patient ID	KRAS status	CTC count ^a	KRAS status	Time point
1	c.35G>A; p.G12D	102	c.35G>A; p.G12D	Prior 1^st line Folfox/Bevacizumab
		12	c.35G>A; p.G12D	Post cycle 1 of 1^st line
		9	NVD	Post cycle 3 of 1^st line
		42	c.35G>A; p.G12D	Post cycle 8 of 1^st line
2	c.35G>A; p.G12D	243	NVD	Prior 1^st line Folfiri
		865	NVD	Progression on 1^st line therapy
3	c.35G>A; p.G12D	1	NVD	Prior 1^st line Folfiri/Bevacizumab
		4	NVD	Post cycle 3 of 1^st line
4	c.34G>T; p.G12C	2	NVD	Prior 1^st line Folfox
5	c.35G>A; p.G12D	3	c.35G>A; p.G12D	Prior 1^st line Folfiri/Bevacizumab
6	c.35G>A; p.G12D	11	c.35G>A; p.G12D	Post cycle 3 of 1^st line Folfox/Bevacizumab
7	c.35G>C; p.G12A	2	NVD	Post cycle 3 of 1^st line Folfox/Bevacizumab
		0	-	Progression on 1^st line therapy
		2	NVD	Post cycle 3 of 2^nd line Folfiri/Bevacizumab
8	c.35G>T; p.G12V	7	c.35G>T; p.G12V	Progression on 1^st line Folfiri/Bevacizumab
		0	-	Post cycle 3 of 2^nd line Folfox/Bevacizumab
9	c.35G>A; p.G12D	0	-	Post cycle 8 of 1^st line Folfiri/Bevacizumab
		0	-	Progression on 1^st line therapy
10	c.38G>A; p.G13D	9	c.38G>A; p.G13D	Post cycle 6 of 1^st line Folfiri/Bevacizumab
11	c.35G>A; p.G12D	0	-	Prior 1^st line Folfiri/Bevacizumab
12	c.35G>A; p.G12D	5	NVD	Prior 1^st line Folfiri/Bevacizumab
13	c.35G>T; p.G12V	4	NVD	Post cycle 1 of 1^st line Folfiri/Bevacizumab
		0	-	Post cycle 3 of 1^st line Folfiri/Bevacizumab
14	c.35G>T; p.G12V	0	-	Post cycle 6 of 1^st line Folfiri/Bevacizumab
		0	-	Progression on 1^st line therapy
		0	-	Palliative care
15	wt	3	NVD	Maintenance therapy with Panitumumab
		42	c.35G>A; p.G12D	Progression on Panitumumab
		10	c.35G>A; p.G12D	Post cycle 2 of 2^nd line Folfiri/Panitumumab
16	wt	7	c.34G>T; p.G12C	Post cycle 1 of 1^st line Folfiri/Bevacizumab
17	wt	0	-	Post cycle 3 of 1^st line Folfiri/Bevacizumab
18	wt	10	NVD	Without treatment
19	wt	660	NVD	Prior 1^st line Folfox/Bevacizumab
20	wt	3	NVD	Prior 1^st line Folfox/Bevacizumab
21	wt	0	-	Prior 1^st line Folfiri/Bevacizumab
		2	NVD	Post cycle 3 of 1^st line therapy
22	wt	0	-	Prior 1^st line Folfiri/Bevacizumab
		0	-	Post cycle 4 of 1^st line therapy
23	wt	0	-	Prior 1^st line Folfox/Bevacizumab
24	wt	17	NVD	Post cycle 6 of 1^st line Folfiri/Bevacizumab
		0	-	Follow up
25	wt	173	NVD	Post cycle 2 of 1^st line Folfiri/Bevacizumab
26	wt	11	NVD	Post cycle 6 of 1^st line Folfox/Bevacizumab
27	wt	8	NVD	Post cycle 6 of 1^st line Xeloda/Bevacizumab
28	wt	0	-	Progression on 1^st line Folfiri/Bevacizumab
29	wt	4	NVD	Progression on 1^st line Folfox/Panitumumab
30	wt	3	NVD	Progression on 1^st line Folfiri/Panitumumab
31	wt	0	-	Progression on 1^st line Folfiri/Bevacizumab

CTC count using CellSearch system depicted as number of cells per 7.5 mL whole blood. Abbreviations: wt; wild type, NVD; no variant detected.